A Systematic Review of Adverse Drug Reactions associated with Thalidomide in the treatment of Erythema Nodosum Leprosum

Background: Erythema nodosum leprosum (ENL) is a painful, multisystem immune mediated complication of borderline lepromatous and lepromatous leprosy. The management of ENL may be complex and often requires prolonged administration of immunomodulatory drugs including thalidomide. Thalidomide is very...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leprosy review 2019-06, Vol.90 (2), p.142-160
Hauptverfasser: Mahmoud, Mariama, Walker, Stephen L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 160
container_issue 2
container_start_page 142
container_title Leprosy review
container_volume 90
creator Mahmoud, Mariama
Walker, Stephen L
description Background: Erythema nodosum leprosum (ENL) is a painful, multisystem immune mediated complication of borderline lepromatous and lepromatous leprosy. The management of ENL may be complex and often requires prolonged administration of immunomodulatory drugs including thalidomide. Thalidomide is very effective in controlling ENL although its mode of action in ENL is not well understood. Teratogenicity and cost limit its use in many settings. In addition to teratogenicity, thalidomide is reported to have a wide range of adverse drug reactions including neurotoxicity. The non-teratogenic adverse drug reactions associated with thalidomide in patients with ENL have not been systematically reviewed. We have reviewed the literature to determine the adverse drug reactions attributable to thalidomide in the management of ENL. Methods: Several databases were searched using the relevant terms. Articles found were reviewed according to the PRISMA protocol. The eligibility of the articles was agreed by both authors. Results: A total of 45 papers from 1965-2017 were systematically reviewed. Eight of these were randomised control trials (RCTs), nine non-randomised clinical trials, three prospective studies, five retrospective studies and 20 case reports. The papers included 1,673 participants with 1,017 (61%) receiving thalidomide. The most frequent adverse drug reaction encountered was drowsiness, in 13.5%. The frequency of constipation was 13.4% and dizziness 6.8%. Other events were reported in less than 5% of participants. Severe adverse reactions such as pulmonary embolism and peripheral neuropathy were uncommon. Only one fatality was reported, the cause of which was uncertain. Thalidomide had to be withdrawn in 67% of individual case reports but only in four patients in the clinical studies. Conclusions: Thalidomide ?s a potentially safe and effective drug for use in the management of ENL. There is limited information about thalidomide-induced neurotoxicity in patients with ENL and this needs further study. Thalidomide is an effective alternative to long-term corticosteroids which have significant adverse effects. It must be administered in a closely supervised way and requires adherence to robust guidelines by prescribers.
doi_str_mv 10.47276/lr.90.2.142
format Article
fullrecord <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A651907247</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651907247</galeid><sourcerecordid>A651907247</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-15376bab1768f09ad7b9a610341e2a854f656222970394d702f55f5fde7495113</originalsourceid><addsrcrecordid>eNptUU1LAzEUXETBWr35AwKCJ3dNsh_ZHEutH1AUtJ5DunnpRnY3JUlb-u_dth5akHd4wzAz8N5E0S3BScYoKx4bl3Cc0IRk9CwaUFLQuCwxOz_Cl9GV9z8Yp4TwdBBtRuhr6wO0MpgKfcLawAZZjUZqDc4DenKrRU_LKhjbeSS9t5WRARTamFCjWS0bo2xrFCDToVADCg5kaKELu5iJ2_ZcK9G7VdavWjSFpduB6-hCy8bDzd8eRt_Pk9n4NZ5-vLyNR9O4ShkJMclTVszlnLCi1JhLxeZcFgSnGQEqyzzTRV5QSjnDKc8Uw1Tnuc61ApbxnJB0GN0dcheyAWE6bYOTVWt8JUZFTjhmNGO9KvlH1Y-C1lS2A216_sRwf2SoQTah9rZZ7b90Knw4CKv-bO9Ai6UzrXRbQbDYlyYaJzgWVPSlpb_NwIiX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Systematic Review of Adverse Drug Reactions associated with Thalidomide in the treatment of Erythema Nodosum Leprosum</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mahmoud, Mariama ; Walker, Stephen L</creator><creatorcontrib>Mahmoud, Mariama ; Walker, Stephen L</creatorcontrib><description>Background: Erythema nodosum leprosum (ENL) is a painful, multisystem immune mediated complication of borderline lepromatous and lepromatous leprosy. The management of ENL may be complex and often requires prolonged administration of immunomodulatory drugs including thalidomide. Thalidomide is very effective in controlling ENL although its mode of action in ENL is not well understood. Teratogenicity and cost limit its use in many settings. In addition to teratogenicity, thalidomide is reported to have a wide range of adverse drug reactions including neurotoxicity. The non-teratogenic adverse drug reactions associated with thalidomide in patients with ENL have not been systematically reviewed. We have reviewed the literature to determine the adverse drug reactions attributable to thalidomide in the management of ENL. Methods: Several databases were searched using the relevant terms. Articles found were reviewed according to the PRISMA protocol. The eligibility of the articles was agreed by both authors. Results: A total of 45 papers from 1965-2017 were systematically reviewed. Eight of these were randomised control trials (RCTs), nine non-randomised clinical trials, three prospective studies, five retrospective studies and 20 case reports. The papers included 1,673 participants with 1,017 (61%) receiving thalidomide. The most frequent adverse drug reaction encountered was drowsiness, in 13.5%. The frequency of constipation was 13.4% and dizziness 6.8%. Other events were reported in less than 5% of participants. Severe adverse reactions such as pulmonary embolism and peripheral neuropathy were uncommon. Only one fatality was reported, the cause of which was uncertain. Thalidomide had to be withdrawn in 67% of individual case reports but only in four patients in the clinical studies. Conclusions: Thalidomide ?s a potentially safe and effective drug for use in the management of ENL. There is limited information about thalidomide-induced neurotoxicity in patients with ENL and this needs further study. Thalidomide is an effective alternative to long-term corticosteroids which have significant adverse effects. It must be administered in a closely supervised way and requires adherence to robust guidelines by prescribers.</description><identifier>ISSN: 2162-8807</identifier><identifier>ISSN: 0305-7518</identifier><identifier>EISSN: 2162-8807</identifier><identifier>DOI: 10.47276/lr.90.2.142</identifier><language>eng</language><publisher>British Leprosy Relief Association</publisher><subject>Adverse and side effects ; Complications and side effects ; Drug therapy ; Drugs ; Erythema nodosum ; Statistics ; Thalidomide</subject><ispartof>Leprosy review, 2019-06, Vol.90 (2), p.142-160</ispartof><rights>COPYRIGHT 2019 British Leprosy Relief Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-15376bab1768f09ad7b9a610341e2a854f656222970394d702f55f5fde7495113</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Mahmoud, Mariama</creatorcontrib><creatorcontrib>Walker, Stephen L</creatorcontrib><title>A Systematic Review of Adverse Drug Reactions associated with Thalidomide in the treatment of Erythema Nodosum Leprosum</title><title>Leprosy review</title><description>Background: Erythema nodosum leprosum (ENL) is a painful, multisystem immune mediated complication of borderline lepromatous and lepromatous leprosy. The management of ENL may be complex and often requires prolonged administration of immunomodulatory drugs including thalidomide. Thalidomide is very effective in controlling ENL although its mode of action in ENL is not well understood. Teratogenicity and cost limit its use in many settings. In addition to teratogenicity, thalidomide is reported to have a wide range of adverse drug reactions including neurotoxicity. The non-teratogenic adverse drug reactions associated with thalidomide in patients with ENL have not been systematically reviewed. We have reviewed the literature to determine the adverse drug reactions attributable to thalidomide in the management of ENL. Methods: Several databases were searched using the relevant terms. Articles found were reviewed according to the PRISMA protocol. The eligibility of the articles was agreed by both authors. Results: A total of 45 papers from 1965-2017 were systematically reviewed. Eight of these were randomised control trials (RCTs), nine non-randomised clinical trials, three prospective studies, five retrospective studies and 20 case reports. The papers included 1,673 participants with 1,017 (61%) receiving thalidomide. The most frequent adverse drug reaction encountered was drowsiness, in 13.5%. The frequency of constipation was 13.4% and dizziness 6.8%. Other events were reported in less than 5% of participants. Severe adverse reactions such as pulmonary embolism and peripheral neuropathy were uncommon. Only one fatality was reported, the cause of which was uncertain. Thalidomide had to be withdrawn in 67% of individual case reports but only in four patients in the clinical studies. Conclusions: Thalidomide ?s a potentially safe and effective drug for use in the management of ENL. There is limited information about thalidomide-induced neurotoxicity in patients with ENL and this needs further study. Thalidomide is an effective alternative to long-term corticosteroids which have significant adverse effects. It must be administered in a closely supervised way and requires adherence to robust guidelines by prescribers.</description><subject>Adverse and side effects</subject><subject>Complications and side effects</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Erythema nodosum</subject><subject>Statistics</subject><subject>Thalidomide</subject><issn>2162-8807</issn><issn>0305-7518</issn><issn>2162-8807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNptUU1LAzEUXETBWr35AwKCJ3dNsh_ZHEutH1AUtJ5DunnpRnY3JUlb-u_dth5akHd4wzAz8N5E0S3BScYoKx4bl3Cc0IRk9CwaUFLQuCwxOz_Cl9GV9z8Yp4TwdBBtRuhr6wO0MpgKfcLawAZZjUZqDc4DenKrRU_LKhjbeSS9t5WRARTamFCjWS0bo2xrFCDToVADCg5kaKELu5iJ2_ZcK9G7VdavWjSFpduB6-hCy8bDzd8eRt_Pk9n4NZ5-vLyNR9O4ShkJMclTVszlnLCi1JhLxeZcFgSnGQEqyzzTRV5QSjnDKc8Uw1Tnuc61ApbxnJB0GN0dcheyAWE6bYOTVWt8JUZFTjhmNGO9KvlH1Y-C1lS2A216_sRwf2SoQTah9rZZ7b90Knw4CKv-bO9Ai6UzrXRbQbDYlyYaJzgWVPSlpb_NwIiX</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Mahmoud, Mariama</creator><creator>Walker, Stephen L</creator><general>British Leprosy Relief Association</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20190601</creationdate><title>A Systematic Review of Adverse Drug Reactions associated with Thalidomide in the treatment of Erythema Nodosum Leprosum</title><author>Mahmoud, Mariama ; Walker, Stephen L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-15376bab1768f09ad7b9a610341e2a854f656222970394d702f55f5fde7495113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adverse and side effects</topic><topic>Complications and side effects</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Erythema nodosum</topic><topic>Statistics</topic><topic>Thalidomide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahmoud, Mariama</creatorcontrib><creatorcontrib>Walker, Stephen L</creatorcontrib><collection>CrossRef</collection><jtitle>Leprosy review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahmoud, Mariama</au><au>Walker, Stephen L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Systematic Review of Adverse Drug Reactions associated with Thalidomide in the treatment of Erythema Nodosum Leprosum</atitle><jtitle>Leprosy review</jtitle><date>2019-06-01</date><risdate>2019</risdate><volume>90</volume><issue>2</issue><spage>142</spage><epage>160</epage><pages>142-160</pages><issn>2162-8807</issn><issn>0305-7518</issn><eissn>2162-8807</eissn><abstract>Background: Erythema nodosum leprosum (ENL) is a painful, multisystem immune mediated complication of borderline lepromatous and lepromatous leprosy. The management of ENL may be complex and often requires prolonged administration of immunomodulatory drugs including thalidomide. Thalidomide is very effective in controlling ENL although its mode of action in ENL is not well understood. Teratogenicity and cost limit its use in many settings. In addition to teratogenicity, thalidomide is reported to have a wide range of adverse drug reactions including neurotoxicity. The non-teratogenic adverse drug reactions associated with thalidomide in patients with ENL have not been systematically reviewed. We have reviewed the literature to determine the adverse drug reactions attributable to thalidomide in the management of ENL. Methods: Several databases were searched using the relevant terms. Articles found were reviewed according to the PRISMA protocol. The eligibility of the articles was agreed by both authors. Results: A total of 45 papers from 1965-2017 were systematically reviewed. Eight of these were randomised control trials (RCTs), nine non-randomised clinical trials, three prospective studies, five retrospective studies and 20 case reports. The papers included 1,673 participants with 1,017 (61%) receiving thalidomide. The most frequent adverse drug reaction encountered was drowsiness, in 13.5%. The frequency of constipation was 13.4% and dizziness 6.8%. Other events were reported in less than 5% of participants. Severe adverse reactions such as pulmonary embolism and peripheral neuropathy were uncommon. Only one fatality was reported, the cause of which was uncertain. Thalidomide had to be withdrawn in 67% of individual case reports but only in four patients in the clinical studies. Conclusions: Thalidomide ?s a potentially safe and effective drug for use in the management of ENL. There is limited information about thalidomide-induced neurotoxicity in patients with ENL and this needs further study. Thalidomide is an effective alternative to long-term corticosteroids which have significant adverse effects. It must be administered in a closely supervised way and requires adherence to robust guidelines by prescribers.</abstract><pub>British Leprosy Relief Association</pub><doi>10.47276/lr.90.2.142</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2162-8807
ispartof Leprosy review, 2019-06, Vol.90 (2), p.142-160
issn 2162-8807
0305-7518
2162-8807
language eng
recordid cdi_gale_infotracmisc_A651907247
source EZB-FREE-00999 freely available EZB journals
subjects Adverse and side effects
Complications and side effects
Drug therapy
Drugs
Erythema nodosum
Statistics
Thalidomide
title A Systematic Review of Adverse Drug Reactions associated with Thalidomide in the treatment of Erythema Nodosum Leprosum
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Systematic%20Review%20of%20Adverse%20Drug%20Reactions%20associated%20with%20Thalidomide%20in%20the%20treatment%20of%20Erythema%20Nodosum%20Leprosum&rft.jtitle=Leprosy%20review&rft.au=Mahmoud,%20Mariama&rft.date=2019-06-01&rft.volume=90&rft.issue=2&rft.spage=142&rft.epage=160&rft.pages=142-160&rft.issn=2162-8807&rft.eissn=2162-8807&rft_id=info:doi/10.47276/lr.90.2.142&rft_dat=%3Cgale_cross%3EA651907247%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A651907247&rfr_iscdi=true